Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MESO | 6-K | mixed | 6/10 | Mesoblast filed its FY2026 annual report (20-F) via a 6-K, reporting first full-year product revenue of $115.2M from Ryo | Oct 13, 2026 |
| ADCT | 8-K | bullish | 7/10 | ADC Therapeutics announced a comprehensive capital restructuring: an $86.6M PIPE (12.9M shares at $1.42 + 48.1M pre-fund | Oct 13, 2026 |
| NRIX | 8-K | bullish | 7/10 | Nurix Therapeutics reported Q3 2026 revenue of $673.1M (vs $7.9M YoY) and net income of $549.8M ($4.73 diluted EPS), mas | Oct 13, 2026 |
| PULM | 425 | neutral | 4/10 | Pulmatrix filed a 425 communication highlighting preclinical data for Eos SENOLYTIX's lead candidate PTC-2105, showing a | Oct 13, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine's 51%-owned subsidiary Charging Robotics launched a next-generation automated EV-charging platform fo | Oct 13, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly B-share repurchases under its existing DKK 15 billion buyback program | Oct 13, 2026 |
| GDTC | SC 13D/A | neutral | 3/10 | Chairman Choo Chee Kong filed an amended Schedule 13D disclosing open-market purchases of 62,000 ordinary shares of Cyto | Oct 13, 2026 |
| TENX | SC 13G/A | bullish | 5/10 | Sphera Funds Management Ltd. and related entities filed an amended Schedule 13G disclosing a 7.09% passive beneficial ow | Oct 13, 2026 |
| AVBP | 8-K | neutral | 4/10 | ArriVent BioPharma dosed the first patient in a Phase 1 U.S. trial for ARR-002, a novel first-in-class MUC16/NaPi2b dual | Oct 13, 2026 |
| ICCC | 8-K | bullish | 6/10 | ImmuCell announced preliminary, unaudited Q3 2026 product sales of $8.0 million, a 46% increase YoY, driven by broad-bas | Oct 13, 2026 |
| BBIO | 8-K | bullish | 7/10 | BridgeBio announced FDA acceptance and Priority Review of its NDA for oral infigratinib for children with achondroplasia | Oct 13, 2026 |
| ZBIO | 8-K | neutral | 4/10 | Zenas BioPharma presented new obexelimab data from the Phase 3 INDIGO open-label extension at the 6th International Symp | Oct 13, 2026 |
| BSEM | EFFECT | bearish | 6/10 | BioStem Technologies' S-1 registration (File No. 333-299282) became effective on October 9, 2026, enabling the company t | Oct 13, 2026 |
| HCWB | EFFECT | bearish | 6/10 | The SEC declared effective HCW Biologics' S-1 registration statement (File No. 333-299271) on October 9, 2026, enabling | Oct 13, 2026 |
| CANF | EFFECT | bearish | 5/10 | Can-Fite BioPharma's F-3 shelf registration (File No. 333-298625) became effective on October 9, 2026. This allows the c | Oct 13, 2026 |
| UPC | EFFECT | bearish | 5/10 | The SEC declared effective Universe Pharmaceuticals' F-3 shelf registration (File No. 333-299191) on October 9, 2026, en | Oct 13, 2026 |
| CANF | EFFECT | bearish | 5/10 | Can-Fite BioPharma Ltd.'s F-3 shelf registration (File No. 333-299160) became effective on October 9, 2026. This allows | Oct 13, 2026 |
| PASG | EFFECT | neutral | 3/10 | Passage BIO's registration statement on Form S-4 (File No. 333-297601) was declared effective by the SEC on October 9, 2 | Oct 13, 2026 |
| NVS | COURT-RULING | bearish | 5/10 | The D.C. District Court entered a final judgment recognizing and enforcing a foreign arbitration award against Novartis | Oct 12, 2026 |
| TWST | CLUSTER | bearish | 6/10 | Six Twist Bioscience insiders, including the CEO, President/COO, and CFO, sold a combined $17.86M in shares over a one-w | Oct 12, 2026 |
| BIIB | ANALYST-UPGRADE | bullish | 6/10 | JP Morgan double-upgraded Biogen (BIIB) from Neutral to Overweight on October 12, 2026, raising the price target to $300 | Oct 12, 2026 |
| GSK | INST-CLUSTER | mixed | 4/10 | Institutional activity in GSK during Q2 2026 was mixed: 29 buyers added $318.7M in new positions (led by Point72 and D.E | Oct 12, 2026 |
| TERN | INST-CLUSTER | bearish | 4/10 | 52 institutional holders completely exited their positions in Terns Pharmaceuticals during Q2 2026, liquidating approxim | Oct 12, 2026 |
| EXEL | INST-CLUSTER | neutral | 3/10 | Institutional activity in EXEL during Q2 2026 was mixed: 45 buyers added $459.5M in net new holdings (led by D.E. Shaw, | Oct 12, 2026 |
| DYN | INST-CLUSTER | mixed | 4/10 | Institutional activity in Dyne Therapeutics (DYN) during Q2 2026 was mixed but skewed bullish by dollar volume: 19 buyer | Oct 12, 2026 |
| DMRA | INST-CLUSTER | neutral | 3/10 | A massive institutional cluster formed in Damora Therapeutics during Q2 2026, with 15 buyers accumulating $139.8M in net | Oct 12, 2026 |
| DNTH | INST-CLUSTER | mixed | 3/10 | Q2 2026 13F filings reveal a mixed institutional cluster in Dianthus Therapeutics (DNTH): 48 buyers added $170.9M in pos | Oct 12, 2026 |
| CGON | INST-CLUSTER | mixed | 3/10 | CG Oncology saw mixed institutional activity in Q2 2026, with 33 buyers adding $166.7M and 22 sellers reducing $129.2M. | Oct 12, 2026 |
| SYRE | INST-CLUSTER | bullish | 4/10 | A large institutional cluster in Spyre Therapeutics (SYRE) for Q2 2026 shows 49 buyers accumulating $878.2M (net +$626.7 | Oct 12, 2026 |
| RVMD | INST-CLUSTER | bullish | 4/10 | A massive institutional cluster formed in Revolution Medicines (RVMD) during Q2 2026, with 92 buyers accumulating $3.03B | Oct 12, 2026 |